Sökning: WFRF:(Grünig Ekkehard)
> (2020) >
Combination Therapy...
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
-
White, R James (författare)
-
Jerjes-Sanchez, Carlos (författare)
-
Bohns Meyer, Gisela Martina (författare)
-
visa fler...
-
Pulido, Tomas (författare)
-
Sepulveda, Pablo (författare)
-
Wang, Kuo Yang (författare)
-
Grünig, Ekkehard (författare)
-
Hiremath, Shirish (författare)
-
Yu, Zaixin (författare)
-
Gangcheng, Zhang (författare)
-
Yip, Wei Luen James (författare)
-
Zhang, Shuyang (författare)
-
Khan, Akram (författare)
-
Deng, C Q (författare)
-
Grover, Rob (författare)
-
Tapson, Victor F (författare)
-
- Hjalmarsson, Clara, 1969 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
visa färre...
-
(creator_code:org_t)
-
-
visa fler...
-
-
visa färre...
- 2020
- 2020
- Engelska.
-
Ingår i: American journal of respiratory and critical care medicine. - 1535-4970. ; 201:6, s. 707-717
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk distance 150 m or greater. The primary endpoint was the time to first adjudicated clinical worsening event: death; hospitalization due to worsening PAH; initiation of inhaled or parenteral prostacyclin therapy; disease progression; or unsatisfactory long-term clinical response.Measurements and Main Results: Clinical worsening occurred in 26% of the oral treprostinil group compared with 36% of placebo participants (hazard ratio, 0.74; 95% confidence interval, 0.56-0.97; P = 0.028). Key measures of disease status, including functional class, Borg dyspnea score, and N-terminal pro-brain natriuretic peptide, all favored oral treprostinil treatment at Week 24 and beyond. A noninvasive risk stratification analysis demonstrated that oral treprostinil-assigned participants had a substantially higher mortality risk at baseline but achieved a lower risk profile from Study Weeks 12-60. The most common adverse events in the oral treprostinil group were headache, diarrhea, flushing, nausea, and vomiting.Conclusions: In participants with PAH, addition of oral treprostinil to approved oral monotherapy reduced the risk of clinical worsening.Clinical trial registered with www.clinicaltrials.gov (NCT01560624).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- clinical study
- combination therapy
- oral treprostinil
- pulmonary arterial hypertension
- sequential therapy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
White, R James
-
Jerjes-Sanchez, ...
-
Bohns Meyer, Gis ...
-
Pulido, Tomas
-
Sepulveda, Pablo
-
Wang, Kuo Yang
-
visa fler...
-
Grünig, Ekkehard
-
Hiremath, Shiris ...
-
Yu, Zaixin
-
Gangcheng, Zhang
-
Yip, Wei Luen Ja ...
-
Zhang, Shuyang
-
Khan, Akram
-
Deng, C Q
-
Grover, Rob
-
Tapson, Victor F
-
Hjalmarsson, Cla ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
American journal ...
- Av lärosätet
-
Göteborgs universitet